11804611|t|Electroencephalographic activation by fluoxetine in rats: role of 5-HT(1A) receptors and enhancement of concurrent acetylcholinesterase inhibitor treatment.
11804611|a|Considerable evidence indicates that both cholinergic (ACh) and serotonergic (5-HT) inputs to the neocortex play a direct role in maintaining the activated state of the electroencephalogram (EEG). Here, we investigated frequency-specific EEG effects of the 5-HT re-uptake inhibitor fluoxetine (10 and 20 mg/kg) to restore EEG activation abolished by combined treatment with the monoamine depletor reserpine (10 mg/kg) and the muscarinic antagonist scopolamine (1 mg/kg). Fluoxetine alone was ineffective in reversing EEG slowing produced by reserpine-scopolamine administration. However, fluoxetine suppressed EEG synchronization in the alpha (8-12 Hz) band when administered concurrently with the 5-HT(1A) receptor antagonist WAY 100635 (0.5 mg/kg). Further, fluoxetine, with and without WAY 100635, markedly potentiated the effectiveness of the acetylcholinesterase (AChE) inhibitor tacrine (5 mg/kg) to restore EEG activation between 4-30 Hz. These data indicate that 5-HT uptake inhibition and concurrent 5-HT(1A) receptor blockade produce a limited normalization of the cortical EEG after monoaminergic-cholinergic blockade. However, fluoxetine strongly potentiates the effectiveness of tacrine to restore EEG activation. Inhibitors of AChE are used to delay cognitive decline and EEG slowing in patients with Alzheimer's disease. We suggest that doses of AChE inhibitors required for these effects can be reduced by concurrent 5-HT stimulation.
11804611	38	48	fluoxetine	Chemical	MESH:D005473
11804611	52	56	rats	Species	10116
11804611	115	135	acetylcholinesterase	Gene	83817
11804611	212	215	ACh	Chemical	MESH:D000109
11804611	221	233	serotonergic	Chemical	-
11804611	235	239	5-HT	Chemical	MESH:D012701
11804611	414	418	5-HT	Chemical	MESH:D012701
11804611	439	449	fluoxetine	Chemical	MESH:D005473
11804611	535	544	monoamine	Chemical	-
11804611	554	563	reserpine	Chemical	MESH:D012110
11804611	605	616	scopolamine	Chemical	MESH:D012601
11804611	628	638	Fluoxetine	Chemical	MESH:D005473
11804611	698	707	reserpine	Chemical	MESH:D012110
11804611	708	719	scopolamine	Chemical	MESH:D012601
11804611	745	755	fluoxetine	Chemical	MESH:D005473
11804611	884	894	WAY 100635	Chemical	MESH:C090413
11804611	917	927	fluoxetine	Chemical	MESH:D005473
11804611	946	956	WAY 100635	Chemical	MESH:C090413
11804611	1004	1024	acetylcholinesterase	Gene	83817
11804611	1026	1030	AChE	Gene	83817
11804611	1042	1049	tacrine	Chemical	MESH:D013619
11804611	1128	1132	5-HT	Chemical	MESH:D012701
11804611	1296	1306	fluoxetine	Chemical	MESH:D005473
11804611	1349	1356	tacrine	Chemical	MESH:D013619
11804611	1398	1402	AChE	Gene	43
11804611	1421	1438	cognitive decline	Disease	MESH:D003072
11804611	1458	1466	patients	Species	9606
11804611	1472	1491	Alzheimer's disease	Disease	MESH:D000544
11804611	1518	1522	AChE	Gene	43
11804611	1590	1594	5-HT	Chemical	MESH:D012701
11804611	Positive_Correlation	MESH:D005473	83817
11804611	Cotreatment	MESH:C090413	MESH:D005473
11804611	Positive_Correlation	MESH:D005473	MESH:D013619
11804611	Association	MESH:D000544	43
11804611	Negative_Correlation	MESH:D013619	83817
11804611	Negative_Correlation	MESH:D005473	MESH:D012701
11804611	Positive_Correlation	MESH:C090413	83817
11804611	Negative_Correlation	MESH:D012701	43
11804611	Association	MESH:D003072	43

